Literature DB >> 35552748

Reply to Roesler et al. concerning the MEVITEM trial.

Didier Frappaz1, Marc Barritault2.   

Abstract

Entities:  

Year:  2022        PMID: 35552748      PMCID: PMC9248393          DOI: 10.1093/neuonc/noac084

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


× No keyword cloud information.
  5 in total

1.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

2.  CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma.

Authors:  Lisa Liang; Ludivine Coudière-Morrison; Nazanin Tatari; Margaret Stromecki; Agnes Fresnoza; Christopher J Porter; Marc R Del Bigio; Cynthia Hawkins; Jennifer A Chan; Timothy C Ryken; Michael D Taylor; Vijay Ramaswamy; Tamra E Werbowetski-Ogilvie
Journal:  Cancer Res       Date:  2018-06-21       Impact factor: 12.701

3.  MEVITEM-a phase I/II trial of vismodegib + temozolomide vs temozolomide in patients with recurrent/refractory medulloblastoma with Sonic Hedgehog pathway activation.

Authors:  Didier Frappaz; Marc Barritault; Laure Montané; Florence Laigle-Donadey; Olivier Chinot; Emilie Le Rhun; Alice Bonneville-Levard; Andreas F Hottinger; David Meyronnet; Anne-Sophie Bidaux; Gwenaële Garin; David Pérol
Journal:  Neuro Oncol       Date:  2021-11-02       Impact factor: 13.029

4.  Antitumor Activities and Cellular Changes Induced by TrkB Inhibition in Medulloblastoma.

Authors:  Amanda Thomaz; Kelly de Vargas Pinheiro; Bárbara Kunzler Souza; Lauro Gregianin; Algemir L Brunetto; André T Brunetto; Caroline Brunetto de Farias; Mariane da Cunha Jaeger; Vijay Ramaswamy; Carolina Nör; Michael D Taylor; Rafael Roesler
Journal:  Front Pharmacol       Date:  2019-06-26       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.